PMID- 17133512
OWN - NLM
STAT- MEDLINE
DCOM- 20070323
LR  - 20220330
IS  - 0885-3185 (Print)
IS  - 0885-3185 (Linking)
VI  - 22
IP  - 2
DP  - 2007 Jan 15
TI  - Long-term tolerability of tetrabenazine in the treatment of hyperkinetic movement 
      disorders.
PG  - 193-7
AB  - We sought to review the long-term tolerability of tetrabenazine (TBZ) and seek 
      determinants of tolerability in the treatment of hyperkinetic movement disorders. 
      A retrospective chart review was performed on patients treated with TBZ between 
      1997 and 2004. Efficacy of TBZ was assessed by a 1- to 5-point response scale (1 
      = marked reduction in abnormal movements, 5 = worsening). All adverse events 
      (AEs) were captured according to their relationship with study drug. A total of 
      448 patients (42% male) were treated for a variety of hyperkinesias, including 
      tardive dyskinesia (n = 149), dystonia (n = 132), chorea (n = 98), tics (n = 92), 
      and myoclonus (n = 19). The mean age at onset of the movement disorder was 43.0 
      +/- 24.2 years, with TBZ starting at a mean age of 50.0 +/- 22.3 years. Patients 
      remained on treatment for a mean of 2.3 +/- 3.4 years. An efficacy response 
      rating of 1 or 2 was sustained in the majority of patients between the first and 
      last visit. Common AEs included drowsiness (25.0%), Parkinsonism (15.4%), 
      depression (7.6%), and akathisia (7.6%). Comparison of log-likelihood ratios 
      revealed that age was a reliable predictor of Parkinsonism (P < 0.0001). TBZ is a 
      safe and effective drug for the long-term treatment of hyperkinetic movement 
      disorders.
CI  - (c) 2006 Movement Disorder Society.
FAU - Kenney, Christopher
AU  - Kenney C
AD  - Parkinson's Disease Center and Movement Disorders Clinic, Department of 
      Neurology, Baylor College of Medicine, Houston, Texas 77030, USA. kenney@bcm.edu
FAU - Hunter, Christine
AU  - Hunter C
FAU - Jankovic, Joseph
AU  - Jankovic J
LA  - eng
PT  - Journal Article
PL  - United States
TA  - Mov Disord
JT  - Movement disorders : official journal of the Movement Disorder Society
JID - 8610688
RN  - 0 (Anti-Dyskinesia Agents)
RN  - Z9O08YRN8O (Tetrabenazine)
SB  - IM
MH  - Adult
MH  - Age of Onset
MH  - Anti-Dyskinesia Agents/administration & dosage/adverse effects/*therapeutic use
MH  - Drug Administration Schedule
MH  - *Drug Tolerance/physiology
MH  - Dyskinesia, Drug-Induced/drug therapy/epidemiology/physiopathology
MH  - Female
MH  - Humans
MH  - Huntington Disease/epidemiology/etiology/physiopathology
MH  - Hyperkinesis/*drug therapy/epidemiology/*physiopathology
MH  - Male
MH  - Middle Aged
MH  - Myoclonus/drug therapy/epidemiology/physiopathology
MH  - Parkinsonian Disorders/drug therapy/epidemiology/physiopathology
MH  - Prevalence
MH  - Retrospective Studies
MH  - Severity of Illness Index
MH  - Tetrabenazine/administration & dosage/adverse effects/*therapeutic use
MH  - Tics/drug therapy/epidemiology/physiopathology
MH  - Time
EDAT- 2006/11/30 09:00
MHDA- 2007/03/24 09:00
CRDT- 2006/11/30 09:00
PHST- 2006/11/30 09:00 [pubmed]
PHST- 2007/03/24 09:00 [medline]
PHST- 2006/11/30 09:00 [entrez]
AID - 10.1002/mds.21222 [doi]
PST - ppublish
SO  - Mov Disord. 2007 Jan 15;22(2):193-7. doi: 10.1002/mds.21222.